KalVista's journey to FDA approval wasn't smooth sailing, with an unexpected delay and alleged behind-the-scenes drama at the ...

Mustang Bio shares more than quadrupled, to $5.23, after the company on Monday said the Food and Drug Administration granted orphan drug designation to Mustang for MB-101 for the treatment of ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...

The FDA approves a rapid test for identifying patients with NSCLC eligible for sunvozertinib, enhancing timely, precision ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...

Johnson & Johnson’s Abiomed has recalled automated controllers for its Impella heart pumps over a fault linked to three ...

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...

New and Unprecedented Survival, Respiratory, and Biomarker Data Prove that NurOwn Helps People with ALS Live Longer and Live ...

Intense throat pain is a key symptom of COVID-19 variant NB.1.8.1, referred to as "razor blade throat." Here's what to know.

The FDA has approved Gamifant for the treatment of adult and pediatric patients with HLH/MAS in known or suspected Still disease.